Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06692712 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.
A Phase 3 study of Hereditary Spastic Paraplegia Type 50, sponsored by Elpida Therapeutics SPC.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06692712: Recruiting Phase 3 study of Hereditary Spastic Paraplegia Type 50, sponsored by Elpida Therapeutics SPC.
NCT06692712 is a Phase 3 study of Hereditary Spastic Paraplegia Type 50 that is actively recruiting participants, run by Elpida Therapeutics SPC. The registered enrollment target is 24 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06692712, a Phase 3 study of Hereditary Spastic Paraplegia Type 50, is actively recruiting participants, sponsored by Elpida Therapeutics SPC.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
Primary Outcome
Change in total percent score of the 8 Major Motor Milestone Scores from baseline in treated group compared to change in total percent score of the 8 Major Motor Milestone Scores from baseline in untreated controls 1. #24: Sit on mat: Maintain, arms free, 3 seconds 2. #38: Prone: Creeps forward 1.8m (6') 3. #52: On the floor: Pulls to stand at large bench 4. #67: Standing: 2 hands held: walks forward 10 steps 5. #69: Standing: Walks forward 10 steps 6. #84: Standing: Holding 1 rail: walks up 4
Conditions Studied
Interventions
- GENETIC MELPIDA
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
Other
- Sant Joan de Deu - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 3 |
What NCT06692712 shows while recruiting
NCT06692712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Hereditary Spastic Paraplegia Type 50 appearing as the primary indexed condition, and to 1 intervention - of which MELPIDA is the first listed.
NCT06692712 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT06692712 about?
NCT06692712 is a clinical study titled "Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.". Phase 3, open-label study to assess the efficacy and safety of a single lumbar intrathecal administration of MELPIDA in individuals with Hereditary Spastic Paraplegia Type 50 (SPG50).
What is the current status of trial NCT06692712?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-02-01. Estimated completion is 2032-06-01.
What conditions does trial NCT06692712 study?
This clinical trial studies the following conditions: Hereditary Spastic Paraplegia Type 50.
What interventions are being tested in trial NCT06692712?
The interventions under investigation include: MELPIDA (GENETIC).
Who is sponsoring clinical trial NCT06692712?
This trial is sponsored by Elpida Therapeutics SPC, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06692712 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06692712's enrollment target sits among peer trials
24 1944th of 2000 higher than 49 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI